First drug safety report
This article was originally published in The Tan Sheet
Executive Summary
FDA posts its first quarterly report of drugs under investigation for potential safety issues based on adverse event reports. The report meets a provision of the Food and Drug Administration Amendments Act and is intended to increase transparent communication. Published Sept. 5, the inaugural report lists 20 drugs and their potential adverse effects that FDA identified between January and March. For example, the list includes duloxetin (Eli Lilly's Cymbalta) for possible urinary retention. While the first report lists only prescription drugs, future reports could include OTC drugs. FDA stresses consumers should not stop taking a drug just because it appears on the list. The agency says its communication is preliminary and an investigation may determine an adverse event is not drug-related
You may also be interested in...
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.
Roche Gets Adjuvant ALK+ Lung Cancer To Itself With Alecensa Approval
The US FDA cleared Roche’s supplemental approval request for ALK inhibitor Alecensa in ALK-positive non-small cell lung cancer following tumor resection.